- $4.98m
- $12.43m
- $1.73m
Brief: Volitionrx Ltd Passed Resolution To Increase Board Size To Seven Members
Brief: Volitionrx Says Board Has Determined To Reduce Size Of Board From Eight To Six Directors
Brief: Volition Appoints Dr Andrew Retter As Chief Medical Officer
Brief: Volitionrx Secures Approximately $5.5 Million In Belgium Regional Government Financing From Wallonie Entreprendre
Brief: Volition And VPG Launch Nu.Q® Vet Cancer Test In UK & Ireland
Brief: VolitionRX Presents Three Cancer Detection Abstracts At Esmo 2023
Brief: Volitionrx Limited Announces Pricing Of $16.5 Million Underwritten Public Offering Of Common Stock
Brief: VolitionRX Announces Proposed Underwritten Public Offering Of Common Stock
Brief: Volitionrx Reports Cash And Cash Equivalents As Of March 31, 2023 At $10 Million
Brief: Volitionrx Limited Announces Closing Of $8.7 Million Underwritten Public Offering Of Common Stock
Expects To Report Holding Approximately $10.9 Million In Cash And Cash Equivalents As Of December 31, 2022
Brief: VolitionRX Ltd Announces Proposed Underwritten Public Offering Of Common Stock
Brief: Volition Announces Expansion Of Availability Of The Nu.Q Vet Cancer Test Through Idexx's Reference Laboratory Network
Brief: VolitionRx Says Cash, Cash Equivalents As Of Sep 30, 2022, Totaled About $16.4 Mln Compared With $16.7 Mln At Quarter Ended June 30, 2022
Brief: Volition Signs Global Supply Agreement For Nu.Q Vet Cancer Test
Brief: Volitionrx Says Board Passed A Resolution To Increase Size Of Board To Nine Members
Brief: VolitionRX appoints Mickie Henshall as an independent director
Brief: Volition Announces U.S. Clinical Study For Nets
Brief: Volitionrx Limited Announces Closing Of $6.9 Million Underwritten Public Offering Of Common Stock